May 16, 2022
Avilar Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Protein Degradation, Chemistry, Genetics, and Drug Discovery
Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the formation of its Scientific Advisory Board (SAB) comprised of an esteemed group of leading scientists with expertise in protein degradation, chemistry, genetics, and drug discovery.
May 03, 2022
Avilar Therapeutics Executives to be Featured Speakers on Advances in Protein Degradation at Upcoming Drug Discovery Conferences
WALTHAM, Mass., May 3, 2022 – Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that members of the company’s leadership team will be featured speakers on advances in the protein degradation field at two upcoming drug discovery conferences. Effie Tozzo, PhD, Chief Scientific Officer of Avilar, will deliver a keynote address […]
April 19, 2022
Avilar Therapeutics to Present Scientific Poster on ATACs, a New Class of Degraders for Targeting Extracellular Proteins, at Upcoming Protein Degradation Conference
WALTHAM, Mass., April 19, 2022 – Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced a scientific poster presentation highlighting ATACs (ASGPR-Targeting Chimeras) at the 5th annual Protein Degradation Using PROTACs & Molecular Glues meeting being held in San Diego, April 19-20. ATACs are a new class of degraders designed to degrade […]
March 14, 2022
Avilar Therapeutics, a biopharmaceutical company focused onextracellular protein degradation, today announced that Daniel Grau, CEO and President, will present at the upcoming Guggenheim Targeted Protein Degradation Day at 2:00PM – 2:30PM on Wednesday, March 16, 2022.
November 18, 2021
Avilar Therapeutics Launches with $60 Million Seed Financing to Pioneer Extracellular Protein Degradation
Company founded and financed by RA Capital Management with vision to extend protein degradation beyond intracellular proteins. Proprietary platform enables creation of novel degraders called ATACs to treat wide range of diseases.